Overview: NGS Glaucoma Sequencing TestIntroduction: The NGS Glaucoma Sequencing Test sequences genes to diagnose glaucoma, causing vision loss or eye pressure. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected hereditary glaucoma.
Other Names: Glaucoma Assay, MYOC/OPTN Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Glaucoma sequencing began in the 1990s with ocular genetic research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose glaucoma, guides treatment, and evaluates patients with vision loss or eye pressure.
Test Parameters: 1. Glaucoma Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision loss, eye pressure, or glaucoma symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision loss, elevated intraocular pressure, or family history of glaucoma. Include current medications, especially eye drops.
Consent: Written consent required, detailing the tests purpose, glaucoma implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze glaucoma genes (e.g., MYOC, OPTN). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for glaucoma diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm hereditary glaucoma, guiding medical or surgical therapy. Negative results may require clinical evaluation.
Specialist Consultation: Consult an ophthalmologist for result interpretation and treatment planning.
Additional Supporting Tests: Tonometry, visual field testing, or optic disc imaging to confirm glaucoma diagnosis.
Test Limitations: Not all glaucoma cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO Glaucoma Guidelines, 2023; Ophthalmology, Wiggs JL, 2022.
